Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine vs Digoxin for Rate Control in AF and HF
NCT04308031Phase 3Unknown
- Start
- Aug 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ivabradine in Atrial fibrillation (AFib) and heart failure (HF) (2 arms). Primary endpoints: Heart rate change at 16 weeks, 6 minute walk test change at 16 weeks and 2 more. Status: unknown.
02
Drugs
ivabradine
03
Conditions
Atrial fibrillation (AFib)heart failure (HF)
Beyond the preview
Go deeper on NCT04308031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04308031.